Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Change in Acquisitions & Divestments (2023 - 2025)

Historic Change in Acquisitions & Divestments for BioRestorative Therapies (BRTX) over the last 3 years, with Q3 2025 value amounting to $2.5 million.

  • BioRestorative Therapies' Change in Acquisitions & Divestments fell 6083.0% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year decrease of 3405.49%. This contributed to the annual value of $21.5 million for FY2024, which is 259.62% up from last year.
  • According to the latest figures from Q3 2025, BioRestorative Therapies' Change in Acquisitions & Divestments is $2.5 million, which was down 6083.0% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, BioRestorative Therapies' Change in Acquisitions & Divestments ranged from a high of $7.1 million in Q3 2023 and a low of $2.5 million during Q3 2025
  • Over the past 3 years, BioRestorative Therapies' median Change in Acquisitions & Divestments value was $4.1 million (recorded in 2024), while the average stood at $4.7 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first surged by 4394.42% in 2024, then tumbled by 6083.0% in 2025.
  • Over the past 3 years, BioRestorative Therapies' Change in Acquisitions & Divestments (Quarter) stood at $2.9 million in 2023, then surged by 43.94% to $4.1 million in 2024, then plummeted by 38.43% to $2.5 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $2.5 million for Q3 2025, versus $3.2 million for Q2 2025 and $3.5 million for Q1 2025.